Phio Pharmaceuticals (PHIO): Operating Sales Margin

Phio Pharmaceuticals Corp (PHIO) - corporate logo

Phio Pharmaceuticals is implementing the INTASYL platform to combat solid tumors, which entails intensive research expenditures and financial pressure. The operating margin distribution clearly captures these expenses, where 0.00 serves as the current metric level. The situation is stabilized by a unique RNA therapy delivery method, allowing the company to generate significant royalties from pharmaceutical behemoths.

PHIO - Phio Pharmaceuticals Corp Operating Profit Ratio over the range 07/04/2022 - 11/19/2026

Analytical breakdowns for Phio Pharmaceuticals

- share price and consensus valuation forecast:
Basic company analysis:PHIO, Phio Pharmaceuticals Corp.
Finished products of Phio Pharmaceuticals Corp.

For the small-cap biotech Phio Pharmaceuticals (PHIO), which competes in narrow immuno-oncology niches, operating margin dynamics serve as an indicator of cost management efficiency during early-stage development. This ratio determines the portion of operating profit before interest and taxes in every dollar of revenue, allowing investors to assess the actual profitability of the business model regardless of debt load or tax regime.

Key competitors

Operating Sales Margin TEM|QGEN - Operating Profitability Margin|Operating Margin IONS|RGEN - Operating Return on Sales|Operating Profitability Avidity RNA|Operating Margin CRISPR Therapeutics Corp CRSP|GeneDx Corp - Operating Margin|Ultragenyx Pharma (RARE) - Operating Sales Margin|beamtx.com (BEAM) - Operating Profitability|SRPT: Operating Profit Ratio|Operating Sales Margin TWST|TXG - Operating Profitability Margin|Operating Margin NTLA|Profitability of Operations Stoke Therapeutics|Operating Profitability BioLife Solutions BLFS|Wave Life Sciences (WVE) - Operating Return on Sales|Maze Therapeutics, Inc. - Operating Margin|Profitability of Operations Sionna Therapeutics, Inc. SION|Prime Medicine Bio (PRME) - Operating Profitability|TSHA: Operating Profit Ratio|Operating Profitability uniQure Pharma|MGTX - Operating Profitability Margin|Operating Margin RGNX|Operating Profitability SLDB (Solid Biosciences)|Ocugen Corp - Operating Sales Margin|PACB: Return on Sales by Operating Profit|benitec.com - Operating Margin|DSGN - Operating Margin|RCKT: Operating Margin|FDMT (4D Molecular Therapeutics Inc) - Operating Profitability|Operating Sales Margin LXEO|Operating Profitability KRRO|Operating Margin EDIT|SLN - Operating Return on Sales|Operating Margin PRQR (ProQR)|CDXS - Operating Sales Margin|Sangamo Therapeutics Inc. - Operating Margin|NAUT - Operating Margin|MGX: Operating Margin|Operating Sales Margin Precision BioSciences, Inc.|GBIO (Generation Bio) - Operating Margin|Boundless Bio Inc. (BOLD) - Profitability of Operations|Operating Sales Margin XCUR (exicuretx.com)|Imunon Inc - Return on Sales by Operating Profit|Mustang Bio, Inc. - Operating Sales Margin|RNAZ - Operating Sales Margin|BNGO: Operating Sales Margin|APDN (Applied DNA Sciences Inc) - Return on Sales by Operating Profit|BLUE (Bluebird Bio) - Operating Sales Margin|ImmunoPrecise Antibodies Ltd - Operating Profit Rate|OMGA (Omega Therapeutics Inc) - Operating Margin|Operating Profitability OMIC|Operating Profitability Regulus Therapeutics Inc. (RGLS)|Operating Sales Margin Syros Pharmaceuticals, Inc. SYRS|Telesis Bio - Operating Sales Margin|Operating Profit Rate TCON|UBX - Operating Profitability